BEIGENE: INSIDE INFORMATION - BEIGENE RECEIVES FDA APPROVAL FOR TEVIMBRA (TISLELIZUMAB) FOR THE TREATMENT OF ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER PRIOR CHEMOTHERAPY

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.